NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc., a mid-stage biopharmaceutical company, focuses on developing product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments. Its proprietary Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are anti-infective molecules produced by white blood cells when defending the body against invading pathogens. These compounds could form a platform to create various products to address the needs in the treatment and prevention of bacterial and viral infections. NovaBay company's lead product candidate, NVC-422, is used for the treatment of eye, ear, and sinus infections, and for use in contact lens solutions, as well as to destroy bacteria in the bladder, and bacteria that have formed biofilm within the catheter. It also offers NVC-101, a proprietary solution of hypochlorous acid used as a wound cleanser and debriding agent. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions, as well as an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo, and other dermatological indications. NovaBay company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in August 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California.
Contact Details
Office Address
NovaBay Pharmaceuticals, Inc.
5980 Horton Street, Suite 550
Emeryville, CA, USA 94608
Phone: (510) 899-8800
Fax: (510) 225-0371
Executives
Chairman, Chief Exec. Officer and Pres.
Dr. Ramin Najafi
Chief Financial Officer
Mr. Thomas J. Paulson
.webp)
.webp)
.webp)
.webp)
.webp)
